Öhrling K - Search Results

1

Patient perception of burden of disease and treatment preferences in non-small cell lung cancer: Results from a European survey.

Tufman A, Redmond K, Giannopoulou A, Gonzalez-McQuire S, Varriale P, Geltenbort-Rost L, Öhrling K, Scheffler M. Tufman A, et al. Among authors: ohrling k. Lung Cancer. 2022 Jun;168:59-66. doi: 10.1016/j.lungcan.2022.04.008. Epub 2022 Apr 22. Lung Cancer. 2022. PMID: 35504135 Free article.

2

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.

Lindsay CR, Garassino MC, Nadal E, Öhrling K, Scheffler M, Mazières J. Lindsay CR, et al. Among authors: ohrling k. Lung Cancer. 2021 Oct;160:152-165. doi: 10.1016/j.lungcan.2021.07.005. Epub 2021 Jul 16. Lung Cancer. 2021. PMID: 34417059 Free article. Review.

3

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.

Kerr KM, Bibeau F, Thunnissen E, Botling J, Ryška A, Wolf J, Öhrling K, Burdon P, Malapelle U, Büttner R. Kerr KM, et al. Among authors: ohrling k. Lung Cancer. 2021 Apr;154:161-175. doi: 10.1016/j.lungcan.2021.02.026. Epub 2021 Feb 22. Lung Cancer. 2021. PMID: 33690091 Free article. Review.

4

Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.

Mohr P, Haferkamp S, Pinter A, Weishaupt C, Huber MA, Downey G, Öhrling K, Loquai C, Louie KS. Mohr P, et al. Among authors: ohrling k. Adv Ther. 2019 Jan;36(1):101-117. doi: 10.1007/s12325-018-0850-6. Epub 2018 Dec 7. Adv Ther. 2019. PMID: 30536143 Free PMC article.

5

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.

Middleton MR, Hoeller C, Michielin O, Robert C, Caramella C, Öhrling K, Hauschild A. Middleton MR, et al. Among authors: ohrling k. Br J Cancer. 2020 Sep;123(6):885-897. doi: 10.1038/s41416-020-0994-4. Epub 2020 Jul 27. Br J Cancer. 2020. PMID: 32713938 Free PMC article. Review.

6

Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database.

Louie KS, Banks V, Scholz F, Richter H, Öhrling K, Mohr P, Haferkamp S. Louie KS, et al. Among authors: ohrling k. Future Oncol. 2020 Mar;16(8):317-328. doi: 10.2217/fon-2019-0838. Epub 2020 Feb 13. Future Oncol. 2020. PMID: 32050787

7

A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries.

van Akkooi ACJ, Haferkamp S, Papa S, Franke V, Pinter A, Weishaupt C, Huber MA, Loquai C, Richtig E, Gokani P, Öhrling K, Louie KS, Mohr P. van Akkooi ACJ, et al. Among authors: ohrling k. Adv Ther. 2021 Feb;38(2):1245-1262. doi: 10.1007/s12325-020-01590-w. Epub 2020 Dec 26. Adv Ther. 2021. PMID: 33368016 Free PMC article.

8

Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.

Gutzmer R, Harrington KJ, Hoeller C, Lebbé C, Malvehy J, Öhrling K, Downey G, Dummer R. Gutzmer R, et al. Among authors: ohrling k. Eur J Dermatol. 2018 Dec 1;28(6):736-749. doi: 10.1684/ejd.2018.3447. Eur J Dermatol. 2018. PMID: 30698145 Review.

9

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, Kaufman HL. Andtbacka RHI, et al. J Immunother Cancer. 2019 Jun 6;7(1):145. doi: 10.1186/s40425-019-0623-z. J Immunother Cancer. 2019. PMID: 31171039 Free PMC article. Clinical Trial.

10

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Marabelle A, et al. Among authors: ohrling k. Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423. Ann Oncol. 2018. PMID: 30295695 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters